Include All CSL Behring Country Sites
About CSL Behring
Quality & Safety
CSL Research & Development
European Commission Grants Marketing Authorisation to CSL Behring’s Privigen
in Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)
CSL Behring announced today that the European Commission has granted marketing authorisation for the use of Privigen
(human normal immunoglobulin, IVIg) 10 percent liquid in the treatment of patients with chronic inflammatory demyelinating polyneuropathy (CIDP).
CSL Behring Donates Medicine Used in Treating Bleeding Disorders to World Federation of Hemophilia
As part of its ongoing commitment to the global coagulation disorders community, CSL Behring will again donate factor product to the World Federation of Hemophilia (WFH) in connection with World Haemophilia Day this month.
CSL Behring enrolls first patient in global paediatric Phase III pivotal study of recombinant fusion protein linking coagulation factor IX with albumin (rIX-FP) to treat haemophilia
CSL Behring has announced that the first patient has been enrolled in the pivotal paediatric phase III study to evaluate the safety, efficacy and pharmacokinetics of recombinant fusion protein linking coagulation factor IX with recombinant albumin (rIX-FP) in previously treated children (up to age 11 years).
CSL Behring Seeks Proposals for the Third Annual Interlaken Leadership Awards
Committed to improving the quality of life for people with rare and serious diseases, CSL Behring is calling for proposals for the 2013 Interlaken Leadership Awards.
Phase II Study Indicates that Fibrinogen Concentrate Given as a First-Line Therapy Significantly Reduces Need for Transfusion after Aortic Surgery
Haywards Heath, UK –December 19, 2012–Clinical study results published today in the journal
showed that human fibrinogen concentrate can significantly reduce the need for blood transfusion when given as an intra-operative, targeted first-line haemostatic therapy in bleeding patients undergoing aortic replacement surgery.
CSL Behring Corporate
CSL Plasma USA
CSL Plasma Services Germany
© 2013 CSL Behring